Pentastarch versus albumin in cardiopulmonary bypass prime: impact on blood loss.
BACKGROUND
Albumin is commonly used as a volume expander in cardiopulmonary bypass (CPB) prime. Pentastarch, a low molecular weight hetastarch, may provide similar efficacy at decreased cost but is known to alter coagulation profiles. Infectious concerns forced the temporary withdrawal of albumin in our institution. Therefore we evaluated pentastarch as an alternative with regards to perioperative hemostasis and blood loss.


METHODS
One hundred consecutive adult patients undergoing first-time aorto-coronary bypass were given 750 mL of 10% pentastarch (represented as P in calculations) diluted in 1000 mL of Ringer's solution added in their CPB prime. A similar control group of 100 consecutive patients had received 200 mL of 25% albumin (represented as A in calculations) diluted in 1500 mL of Ringer's solution.


RESULTS
Postoperative prothrombin time (PT) was slightly higher with pentastarch (P: 14.9 +/- 1.5 seconds, A: 14.2 +/- 1.3 seconds, p = 0.003). Postoperative bleeding was also increased (P: 2337 +/- 1242 mL, A: 1981 +/- 1121 mL, p = 0.034), mostly because of recirculated shed mediastinal blood (P: 834 +/- 499 mL, A: 640 +/- 388, p = 0.002) rather than lost pleural tube blood (P: 1503 +/- 821 mL, A: 1341 +/- 824 mL, p = 0.16). Overall net blood loss (P: 2014 +/- 914 mL, A: 2061 +/- 1015, p = 0.73) was similar. Blood-product transfusion requirements and postoperative daily hematocrits did not differ.


CONCLUSIONS
The diminished coagulability associated with this dose of pentastarch resulted in increased postoperative bleeding. However, with recirculation of shed mediastinal blood, there was no net increase in blood loss. In this setting, pentastarch may serve as a suitable alternative to albumin.
Keyser
E J
EJ
Division of Cardiothoracic Surgery, McGill University Health Center, Montreal, Quebec, Canada.
Latter
D A
DA
Morin
J E
JE
Murshid
A A
AA
Denis
F
F
de Varennes
B
B
D000368:Aged; D000418:Albumins / Q000627:therapeutic use*; D001802:Blood Substitutes / Q000627:therapeutic use*; D001803:Blood Transfusion; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass; D005260:Female; D006488:Hemostasis, Surgical / Q000379:methods*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
D000418:Albumins; D001802:Blood Substitutes; D006895:Hydroxyethyl Starch Derivatives